Related Experiment Videos
Cholinergic neuropharmacology: an update.
J M Palacios1, H W Boddeke, E Pombo-Villar
1Preclinical Research, Sandoz Pharma Ltd., Basle, Switzerland.
Acta Psychiatrica Scandinavica. Supplementum
|January 1, 1991
Summary
This review examines central cholinergic transmission pharmacology for treating mental disorders like dementia. Promising therapeutic agents include specific acetylcholinesterase inhibitors and selective muscarinic receptor modulators.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Central cholinergic system plays a crucial role in cognitive functions.
- Dysfunction in cholinergic transmission is implicated in mental disorders, especially senile dementia.
Purpose of the Study:
- To review the current pharmacology of central cholinergic transmission.
- To identify potential therapeutic agents for mental disorders, focusing on senile dementia.
Main Methods:
- Review of compounds affecting acetylcholine synthesis, storage, and release.
- Analysis of acetylcholinesterase inhibitors.
- Examination of agents acting on nicotinic and muscarinic cholinergic receptors.
Main Results:
- Several classes of compounds show potential for treating cognitive decline.
- Acetylcholinesterase inhibitors and selective muscarinic receptor subtype modulators are highlighted.
Conclusions:
- Specific acetylcholinesterase inhibitors represent a promising therapeutic strategy.
- Targeting single muscarinic cholinergic receptor subtypes offers a refined approach for drug development.